Defining extended half-life rFVIII-A critical review of the evidence.

Mahlangu, J; Young, G; Hermans, C; Blanchette, V; Berntorp, E; Santagostino, E

Mahlangu, J; Young, G; Hermans, C; Blanchette, V; Berntorp, E; Santagostino, E.

Afiliación

Mahlangu J; Faculty of Health Sciences, University of the Witwatersrand and National Health Laboratory Service, Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa.
Young G; Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA, USA.
Hermans C; Haemostasis and Thrombosis Unit, Division of Haematology, Cliniques universitaires Saint-Luc, Brussels, Belgium.
Blanchette V; Pediatric Thrombosis and Hemostasis Program, Division of Hematology/Oncology, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.
Berntorp E; Centre for Thrombosis and Haemostasis, Lund University, Malmö, Sweden.
Santagostino E; A. Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Ca' Granda Foundation, Maggiore Hospital Policlinico of Milan, Milan, Italy.

Haemophilia ; 24(3): 348-358, 2018 May.

Article en En | MEDLINE | ID: mdl-29633467

Asunto(s)

Factor VIII/farmacocinética; Proteínas Recombinantes/farmacocinética; Animales; Factor VIII/uso terapéutico; Semivida; Humanos; Proteínas Recombinantes/uso terapéutico; Equivalencia Terapéutica

Palabras clave

bioequivalence; extended half-life; haemophilia A; prophylaxis; recombinant factor VIII

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Proteínas Recombinantes / Factor VIII Tipo de estudio: Prognostic_studies / Systematic_reviews Límite: Animals / Humans Idioma: En Revista: Haemophilia Asunto de la revista: HEMATOLOGIA Año: 2018 Tipo del documento: Article País de afiliación: Sudáfrica

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google